NCT00198133View on ClinicalTrials.gov

Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

December 31, 2006

Study Completion Date

May 31, 2012

Conditions
ThymomaThymic Carcinoma
Interventions
DRUG

Premetrexed (Alimta)

Pemetrexed will be 500 mg/m2 IV every 3 weeks

Trial Locations (1)

46202

Indiana University Cancer Center, Indianapolis

All Listed Sponsors
lead

Patrick Joseph Loehrer Sr.

OTHER

NCT00198133 - Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma | Biotech Hunter | Biotech Hunter